Table 7.
The effect of chemotherapy on CVD risk between PCNSLs and NCNSLs.
| Variable | Before PSM | After PSM | ||
|---|---|---|---|---|
| HR (95% CI) | P Value | HR (95% CI) | P Value | |
| Unadjusted HR | ||||
| PCNSL | 0.620 (0.440–0.874) | 0.006 | 0.642 (0.443–0.931) | 0.019 |
| NCNSL | Reference | Reference | ||
| Model 1 a | ||||
| PCNSL | 0.579 (0.410–0.818) | 0.002 | 0.636 (0.439–0.923) | 0.017 |
| NCNSL | Reference | Reference | ||
| Model 2 b | ||||
| PCNSL | 0.608 (0.430–0.859) | 0.005 | 0.640 (0.441–0.928) | 0.019 |
| NCNSL | Reference | Reference | ||
a
In model 1, hazard ratios were adjusted for statistically significant factors according to univariate analysis (age at diagnosis and year of diagnosis).
b
In model 2, hazard ratios were adjusted for all factors in model 1, plus the potential confounders (sex, race, marital status, histological type, and surgery).
HR, hazard ratios; NCNSL, non-central nervous system lymphoma; PCNSL, primary central nervous system lymphoma; PSM, propensity score matching; 95% CI, 95% confidence interval.
The bold values mean P value < 0.05.